For decades, the search for an Alzheimer's treatment has focused on clearing the brain of its accumulated debris — the amyloid plaques long thought to be the disease's signature. Now, researchers at the Centre for Addiction and Mental Health have spent twelve years arriving at a different question: what if the goal is not to remove what is broken, but to restore what has gone silent? Their compound, GL-II-73, works by reawakening GABA receptors in the hippocampus, and in mice engineered to forget, it has — sometimes with a single dose — given memory back. Human trials are expected to begin in
Experimental Alzheimer's drug restores memory in mouse studies, heads to human trials
A single dose reversed memory deficits entirely in early-stage disease
Mark
Why does it matter that this drug works on GABA receptors instead of targeting amyloid like most other Alzheimer's drugs?
Mimi
Because amyloid is a symptom, not necessarily the root cause. You can clear plaques from the brain and patients still decline. This drug goes after the actual machinery—the connections between neurons. It's trying to fix what's broken, not just clean up the debris.
Mark
The mouse studies showed it worked best with a single dose early on. Does that mean it only works if you catch Alzheimer's very early?
Mimi
Not entirely. Even in older mice with more advanced disease, chronic treatment still helped. It was less dramatic, but the memory improved. That suggests there's a window, but it's not a cliff—you don't lose all benefit if you start later.
Mark
Fifty million people worldwide have Alzheimer's. How realistic is it that this drug could reach them?
Mimi
That's the hard part. Right now it's a mouse. Phase 1 trials will tell us if it's safe in humans. Then you need Phase 2 and Phase 3 to prove it actually works. Even if everything goes perfectly, we're talking years before it could be prescribed widely. But the fact that it's moving to human trials at all is significant.
Mark
What happens if the Phase 1 trial shows the drug is safe but doesn't work in people the way it worked in mice?
Mimi
That's the most likely outcome, honestly. Animal models don't always translate. But the mechanism is sound—GABA dysfunction is real in Alzheimer's brains. If this particular compound doesn't work, the pathway itself might still be worth pursuing with different drugs.
El Pulso
- A single dose of GL-II-73 erased memory deficits in early-stage Alzheimer's mice, restoring their performance to match that of healthy animals — a result researchers called 'incredible.'
- The drug bypasses the long-contested amyloid hypothesis entirely, instead targeting GABA receptors in the hippocampus to rebuild the neural connections that learning and memory depend on.
- Even in older mice with advanced cognitive decline, chronic treatment still yielded measurable improvement — suggesting the drug's window of benefit may be wider than early results alone imply.
- The FDA has cleared GL-II-73 for human testing, and Damona Pharmaceuticals — the CAMH spinout formed to carry this research forward — plans to enroll Phase 1 trial participants in the first half of 2025.
- The leap from mouse model to human patient remains the most uncertain crossing in medicine, but the consistency of results across disease stages has given researchers and investors alike reason to watch closely.
For decades, the search for an Alzheimer's treatment has focused on clearing the brain of its accumulated debris — the amyloid plaques long thought to be the disease's signature. Now, researchers at the Centre for Addiction and Mental Health have spent twelve years arriving at a different question: what if the goal is not to remove what is broken, but to restore what has gone silent? Their compound, GL-II-73, works by reawakening GABA receptors in the hippocampus, and in mice engineered to forget, it has — sometimes with a single dose — given memory back. Human trials are expected to begin in the first half of 2025, carrying with them the quiet weight of fifty million lives.
Researchers at the Centre for Addiction and Mental Health have spent twelve years developing a compound called GL-II-73, and the results in animal models have been striking enough to earn FDA clearance for human trials. Published in Neurobiology of Aging, the work represents a meaningful departure from the dominant logic of Alzheimer's research — rather than targeting the amyloid plaques that accumulate in affected brains, GL-II-73 works by restoring GABA receptors in the hippocampus, effectively repairing the neural architecture that memory depends on.
The research team, led by Drs. Etienne Sibille and Thomas Prevot, tested the drug across two populations of mice — normal animals and those genetically predisposed to Alzheimer's — using both single-dose and four-week treatment protocols. In younger mice showing early-stage symptoms, a single dose was enough to eliminate memory deficits entirely, bringing their performance in line with healthy controls. In older mice with more advanced decline, the benefits were real but more modest, pointing to a drug that works best early while still offering something to those further along.
The mechanism is what distinguishes GL-II-73 from existing treatments. By targeting GABA receptors in the hippocampus rather than attempting to clear amyloid, the drug appears to grow and reinforce the connections between brain cells — rebuilding the pathways that learning and memory travel along. Dr. Prevot described the compound's capacity to restore cognitive function as remarkable.
In 2019, CAMH spun out Damona Pharmaceuticals to bring GL-II-73 toward clinical use, with applications extending beyond Alzheimer's to depression, schizophrenia, and epilepsy. Damona's CEO John Reilly has announced plans to enroll patients in a Phase 1 trial during the first half of 2025. The distance between a promising mouse study and a proven human therapy is never short, but for the nearly fifty million people living with Alzheimer's worldwide — and for the families beside them — the possibility that this distance is now being crossed carries a weight that is difficult to overstate.
Researchers at the Centre for Addiction and Mental Health have moved an experimental compound called GL-II-73 closer to human testing after demonstrating that it can restore memory function in mice engineered to develop Alzheimer's disease. The work, published in Neurobiology of Aging, represents a shift in how scientists think about treating cognitive decline—rather than targeting the amyloid plaques that accumulate in Alzheimer's brains, this drug works by repairing the neural machinery itself.
Alzheimer's affects nearly 50 million people worldwide and remains the most common form of dementia. It is a progressive disease that erodes memory, thinking ability, and behavior, leaving patients and families struggling with profound loss. Current treatments do not slow or reverse the underlying damage. This new research suggests a different approach might be possible.
Dr. Etienne Sibille and Dr. Thomas Prevot, who lead the Neurobiology of Depression and Aging Program at CAMH, spent 12 years building toward this moment. Their team tested GL-II-73 in two groups of mice: normal animals and genetically modified ones prone to beta-amyloid buildup. Some treated mice received a single dose before memory testing; others underwent four weeks of continuous treatment. The researchers then measured how well the animals could remember and learn.
The results were striking in early-stage disease models. A single dose of GL-II-73 erased the memory deficits in younger mice with Alzheimer's symptoms, allowing them to perform identically to healthy controls. In older mice further along in cognitive decline, chronic treatment still improved memory, though less dramatically—suggesting the drug works best when given early but retains some benefit even after significant damage has occurred.
Unlike drugs that try to clear amyloid from the brain, GL-II-73 takes a different path. It targets GABA receptors in the hippocampus, the brain region critical for forming and storing memories. By restoring these receptors, the drug appears to rebuild damaged neural connections and strengthen the pathways that underlie learning. Dr. Prevot noted that the compound demonstrated "an incredible ability to restore cognitive function," particularly through its capacity to grow and reinforce the connections between brain cells.
The research caught the attention of venture investors. In 2019, CAMH spun out a company called Damona Pharmaceuticals to develop GL-II-73 and related compounds for Alzheimer's, depression, schizophrenia, and epilepsy. The FDA has now cleared the drug for human testing. John Reilly, Damona's CEO, announced that the company plans to enroll patients in a Phase 1 clinical trial during the first half of 2025—the first step in determining whether the promise seen in mice translates to people.
That transition from animal models to human patients is always uncertain. But the specificity of the drug's mechanism, combined with the consistency of the memory improvements across different disease stages in mice, suggests there is genuine biological signal here. If Phase 1 trials proceed without serious safety concerns, the path toward larger efficacy studies will open. For families watching a loved one's mind slip away, the possibility that a drug might one day slow or even reverse that process represents something that has long seemed impossible.
Citas Notables
By restoring neural function and reversing memory deficits, GL-II-73 represents a potential early intervention for Alzheimer's, addressing the root cause of memory loss—something no current drugs can achieve.— Dr. Etienne Sibille, Scientific Director, Neurobiology of Depression and Aging Program at CAMH
GL-II-73 demonstrated an incredible ability to restore cognitive function in a mouse model of Alzheimer's, particularly when administered early in the disease.— Dr. Thomas Prevot, Scientist, Neurobiology of Depression and Aging Program at CAMH
Quieres la nota completa?
Lee el original en News-Medical.net ↗
Health & Medicine